Investor Presentation Full Year 2017
Novo Nordisk at a glance
Investor Presentation
Full year 2017
Slide 23
Global leader in diabetes care
• A focused pharmaceutical company with leading positions in
diabetes, haemophilia and growth hormone
• Significant growth opportunities driven by the diabetes
pandemic, fuelled by global presence and strong research
•
and development pipeline
High barriers to entry in biologics
• Operating profit growth targeting 5% yearly on average
(measured in local currencies)
Earnings conversion to cash targeting 90%
• Cash generated returned to shareholders
Global insulin market leadership
Global insulin market share: 46%
Region Europe:
Market share 44%
North America Operations:
Region China:
Market share 53%
Market share 39%
Region Japan & Korea:
Market share 50%
Region AAMEO:
Market share 55%
Region Latin America:
Market share 42%
Global/regional headquarter
Source: IQVIA (formerly IMS) MAT Nov 2017 volume figures
AAMEO: Africa, Asia, Middle East & Oceania
Manufacturing
R&D facility
changing
diabetes
novo nordiskView entire presentation